Different methylation signatures at diagnosis in patients with high-risk myelodysplastic syndromes and secondary acute myeloid leukemia predict azacitidine response and longer survival

BACKGROUND: Epigenetic therapy, using hypomethylating agents (HMA), is known to be effective in the treatment of high-risk myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) patients who are not suitable for intensive chemotherapy and/or allogeneic stem cell transplantation. However, r...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Clin Epigenetics
Autors principals: Cabezón, M., Malinverni, R., Bargay, J., Xicoy, B., Marcé, S., Garrido, A., Tormo, M., Arenillas, L., Coll, R., Borras, J., Jiménez, M. J., Hoyos, M., Valcárcel, D., Escoda, L., Vall-Llovera, F., Garcia, A., Font, L. L., Rámila, E., Buschbeck, M., Zamora, L.
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2021
Matèries:
Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7809812/
https://ncbi.nlm.nih.gov/pubmed/33446256
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13148-021-01002-y
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars